Spiral Therapeutics Announces First Closing of a Series A Financing and Begins Phase 1 Trial of New Hearing Loss Drug SAN FRANCISCO, December 18, 2018-- Spiral Therapeutics, a clinical stage pharmaceutical company focused on the development of first-in-class therapies targeting inner ear disorders, today announced the initiation of its Phase 1 clinical trial of LPT99, the company's lead investigational drug candidate targeting prevention and treatment of hearing loss.